Audentes Therapeutics, Inc. (BOLD) Cut to Sell at ValuEngine

ValuEngine cut shares of Audentes Therapeutics, Inc. (NASDAQ:BOLD) from a hold rating to a sell rating in a research report sent to investors on Friday morning.

BOLD has been the subject of a number of other research reports. Zacks Investment Research downgraded Audentes Therapeutics from a buy rating to a hold rating in a research note on Tuesday, August 8th. Leerink Swann started coverage on Audentes Therapeutics in a research note on Monday, May 1st. They issued an outperform rating and a $22.00 price target for the company. Finally, Wedbush reaffirmed an ourperform rating and issued a $20.00 price target on shares of Audentes Therapeutics in a research note on Monday, May 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $22.25.

Audentes Therapeutics (NASDAQ:BOLD) opened at 17.50 on Friday. The company’s 50-day moving average is $19.92 and its 200 day moving average is $16.80. Audentes Therapeutics has a 1-year low of $13.06 and a 1-year high of $22.82. The firm’s market capitalization is $383.06 million.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.10. On average, equities analysts expect that Audentes Therapeutics will post ($3.57) EPS for the current fiscal year.

WARNING: This report was reported by [[site]] and is the property of of [[site]]. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at [[permalink]].

In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 2,850 shares of the business’s stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $20.00, for a total transaction of $57,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Louis G. Lange sold 15,000 shares of the business’s stock in a transaction dated Monday, June 26th. The stock was sold at an average price of $19.78, for a total value of $296,700.00. Following the transaction, the director now directly owns 470,799 shares of the company’s stock, valued at approximately $9,312,404.22. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,850 shares of company stock valued at $653,700. Insiders own 47.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. TD Asset Management Inc. increased its position in shares of Audentes Therapeutics by 2.4% in the second quarter. TD Asset Management Inc. now owns 25,280 shares of the biotechnology company’s stock valued at $484,000 after buying an additional 598 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Audentes Therapeutics by 27.1% in the second quarter. ProShare Advisors LLC now owns 15,581 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 3,324 shares during the last quarter. Bank of America Corp DE increased its position in shares of Audentes Therapeutics by 22.6% in the first quarter. Bank of America Corp DE now owns 23,399 shares of the biotechnology company’s stock valued at $399,000 after buying an additional 4,310 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Audentes Therapeutics by 36.2% in the first quarter. Bank of New York Mellon Corp now owns 18,843 shares of the biotechnology company’s stock valued at $321,000 after buying an additional 5,009 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Audentes Therapeutics by 278.5% in the first quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 5,700 shares during the last quarter. 59.76% of the stock is owned by hedge funds and other institutional investors.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

To view ValuEngine’s full report, visit ValuEngine’s official website.